| Bioactivity | Bradykinin is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also recognized as a neuromediator and regulator of several vascular and renal functions. | ||||||
| Invitro | Bradykinin is a potent vasodilator peptide that exerts its vasodilatory action through stimulation of specific endothelial B2 receptors, thereby causing the release of prostacyclin, NO, and EDHF[1]. Bradykinin has been reported to be involved in the progression of many types of cancer. Bradykinin treatment promotes the invasion and migration of colorectal cancer cells. Bradykinin treatment stimulates ERK1/2 activation and IL-6 production[2]. Exogenous bradykinin markedly inhibits TF expression in mRNA and protein level induced by LPS in a dose-dependent manner. The NO synthase antagonist L-NAME and PI3K inhibitor LY294002 dramatically abolish the inhibitory effects of bradykinin on tissue factor expression[3]. | ||||||
| Name | Bradykinin | ||||||
| CAS | 58-82-2 | ||||||
| Formula | C50H73N15O11 | ||||||
| Molar Mass | 1060.21 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
Bradykinin
CAS: 58-82-2 F: C50H73N15O11 W: 1060.21
Bradykinin is an active peptide that is generated by the kallikrein-kinin system. It is a inflammatory mediator and also
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.